Jim Cramer aconseja precaución en Mobileye Global y favorece a Eli Lilly sobre Cassava Sciences en los ensayos de Alzheimer. Jim Cramer advises caution on Mobileye Global and favors Eli Lilly over Cassava Sciences in Alzheimer's trials.

En "Mad Money", el presentador Jim Cramer abordó las consultas sobre acciones durante una ronda relámpago. On "Mad Money," host Jim Cramer addressed stock inquiries during a lightning round. Anotó que aunque Cassava Sciences participa en un ensayo sobre el Alzheimer, la formulación de Eli Lilly se considera superior. He noted that while Cassava Sciences is engaged in an Alzheimer's trial, Eli Lilly's formulation is viewed as superior. Cramer aconsejó cautela con respecto a Mobileye Global, afirmando que evitaría invertir debido a la incertidumbre. Cramer advised caution regarding Mobileye Global, stating he would avoid investing due to uncertainty.